Publications by authors named "Garcia-Vidal C"
Development and Validation of a Machine Learning Model for the Prediction of Bloodstream Infections in Patients with Hematological Malignancies and Febrile Neutropenia.
Antibiotics (Basel)
December 2024
The rise of multidrug-resistant (MDR) infections demands personalized antibiotic strategies for febrile neutropenia (FN) in hematological malignancies. This study investigates machine learning (ML) for identifying patient profiles with increased susceptibility to bloodstream infections (BSI) during FN onset, aiming to tailor treatment approaches. From January 2020 to June 2022, we used the unsupervised ML algorithm KAMILA to analyze data from hospitalized hematological malignancy patients.
View Article and Find Full Text PDFObjectives: We aimed to describe the characteristics of Clostridioides difficile infection (CDI) in cancer patients, analysing risk factors for 90-day recurrence and attributable mortality.
Methods: Retrospective analysis on all CDI episodes from 2020 to 2022 in three Australian hospitals and one Spanish hospital. Logistic regression analyses were performed.
Community-acquired respiratory viral infections (CARV) significantly impact patients with hematological malignancies (HM), leading to high morbidity and mortality. However, large-scale, real-world data on CARV in these patients is limited. This study analyzed data from the EPICOVIDEHA-EPIFLUEHA registry, focusing on patients with HM diagnosed with CARV during the 2023-2024 autumn-winter season.
View Article and Find Full Text PDFBackground: We evaluated the microbial burden on gel polished nails (GPN), standard polished nails (SPN) and unpolished nails (UPN) before and after an alcohol-based hand rub (HHAB).
Methods: Three GPN, two SPN and five UPN in both hands were analyzed in 46 health-care workers volunteers. Nail length was maintained ≤2mm during the study.
Article Synopsis
- * The review focuses on the experience of developing a virtual control center for COVID-19 patients in Spain, showcasing how CDSS allowed for real-time monitoring and improved personalized medical care during the pandemic.
- * While CDSS can enhance patient care quality and increase healthcare efficiency, challenges remain, such as the need for training medical professionals to use the systems effectively and maintaining updated software.
Introduction: Real-world data from multinational observational studies are required to better understand the role and performance of isavuconazole in real-world practice in Europe.
Methods: A retrospective medical record review was conducted at 16 sites in Europe (France, Germany, Italy, Spain, and the United Kingdom). Eligible records were from patients aged ≥ 18 years at the time of isavuconazole initiation and received at least one dose of isavuconazole for suspected or confirmed invasive aspergillosis (IA) or invasive mucormycosis (IM) during the eligibility period (October 15, 2015 to June 30, 2019).
Article Synopsis
- The study aimed to evaluate whether extended infusions (EI) of β-lactam antibiotics are more effective than intermittent infusions (II) in treating febrile neutropenia, a condition common in patients receiving chemotherapy and stem cell transplants.
- In a clinical trial involving 150 patients from four Spanish hospitals, those receiving EI experienced a slightly lower success rate at day 5 compared to those on II (50.6% vs. 63.0%), although not statistically significant.
- The research concluded that routine use of EI for β-lactams in this patient group is not supported, suggesting the need for further studies to address the diverse clinical aspects of febrile neutropenia.
Article Synopsis
- The study analyzed the occurrence of multidrug-resistant (MDR) bacteria in solid cancer patients with bloodstream infections (BSIs) over 25 years, revealing a significant rise in MDR strains, especially ESBL-producing bacteria.
- Among 6,117 BSI episodes, Gram-negative bacilli (GNB) were the most prevalent, and 24.8% of patients received inappropriate empiric antibiotic treatment (IEAT), which correlated with higher mortality rates.
- Risk factors for MDR BSIs included prior antibiotic use, infections occurring during treatment, and specific infection sources, highlighting the need for improved risk assessment and careful antibiotic prescribing to enhance patient outcomes.
Article Synopsis
- Cerebral aspergillosis (CA) has a high mortality rate, and the study focuses on the effectiveness and safety of isavuconazole as a treatment option compared to standard therapies like voriconazole.
- An analysis of 40 patients treated with isavuconazole across 10 countries showed that the drug effectively controlled CA in about 70-73% of cases, with a 12-week mortality rate of 18%.
- The findings suggest that isavuconazole is well-tolerated and can provide similar survival outcomes to voriconazole, making it a viable first-line treatment option for CA.
Background: This study aimed to describe documented infections associated with postinfusion fever after CAR T-cell therapy and to evaluate daily changes in vital signs, laboratory results, and the National Early Warning Score (NEWS) in patients with and without confirmed bacterial infections following fever onset, with the objective of assisting in antibiotic stewardship.
Methods: This was a retrospective, observational study including all consecutive adult patients who received CAR T-cell therapy. Documented infection in the first fever episode after infusion, and clinical and analytic trend comparison of patients with bacterial documented infections and those without documented infections, are described.
Introduction: Despite antifungal advancements, candidaemia still has a high mortality rate of up to 40%. The ECMM Candida III study in Europe investigated the changing epidemiology and outcomes of candidaemia for better understanding and management of these infections.
Methods: In this observational cohort study, participating hospitals enrolled the first ten consecutive adults with blood culture-proven candidemia.
Objectives: To describe the management of haematological patients experiencing prolonged SARS-CoV-2 viral shedding, as the optimal management strategy for this condition remains undetermined.
Methods: We conducted a retrospective evaluation of our prospectively followed cohort of haematological patients treated with remdesivir for more than 10 days. Starting January 2023, upon COVID-19 diagnosis, the treatment strategy was based on symptoms and PCR cycle threshold (Ct) as follows: (i) when Ct was 25 or less or if the patient had symptoms, a course of remdesivir for at least 10 days, nirmatrelvir/ritonavir for 5 days (whenever possible) and convalescent plasma was administered; and (ii) when the patient was asymptomatic and had a PCR Ct of more than 25, when possible, a course of 5 days of nirmatrelvir/ritonavir was administered.
Article Synopsis
- The text refers to a correction made to a previously published article, identified by its DOI number (10.3389/fimmu.2022.1105343).
- Corrections in scientific articles are important to ensure the accuracy and reliability of the research findings.
- The specifics of what was corrected are not mentioned in the text provided.
Article Synopsis
- Researchers studied the rise of azole-resistant invasive aspergillosis in hematology patients in a Spanish hospital over the last 4 months, identifying 4 cases total, with 3 being azole-resistant.
- The diagnostic methods included fungal culture, antifungal susceptibility testing, and real-time PCR for detecting both Aspergillus species and azole resistance mutations like TR34/L98H.
- Findings showed that all azole-resistant cases had significant hematologic conditions and risk factors, indicating a pressing need for better monitoring and development of new antifungal treatments.
Article Synopsis
- - The article discusses four cases of a new carbapenem-resistant bacterial clone (ST179) that was imported from Peru to Spain, affecting leukemia patients and showcasing multidrug resistance but sensitivity to certain antibiotics like fosfomycin and colistin.
- - Whole-genome sequencing showed the resistance genes were carried on a plasmid and an integron, signaling evolving resistance mechanisms that pose a global health threat.
- - It marks the first reported case of this specific strain carrying the blaKPC-35 gene and emphasizes the urgent need for strict infection control to prevent the spread of such drug-resistant bacteria.
This large, multicenter, retrospective cohort study including onco-hematological neutropenic patients with bloodstream infection (PABSI) found that among 1213 episodes, 411 (33%) presented with septic shock. The presence of solid tumors (33.3% vs.
View Article and Find Full Text PDFArticle Synopsis
- The study evaluated the safety and effectiveness of isavuconazole in treating non-neutropenic patients with invasive fungal infections (IFIs) across 12 university hospitals from 2018 to 2022.
- A total of 238 cases were analyzed, with aspergillosis being the most common infection, and only 5.9% of patients experienced toxic effects, mostly related to liver issues.
- The treatment showed a successful clinical response in about 50.5% of patients after 12 weeks, indicating isavuconazole is a viable option for this patient group.
Objectives: De-escalation (DES) from echinocandins to azoles is recommended by several medical societies in Candida infections. We summarise the evidence of DES on clinical and microbiological cure and 30-day survival and compare it with continuing the treatment with echinocandins (non-DES).
Methods: We searched MEDLINE, Embase, Web of Science and Scopus.
Article Synopsis
- The COVID-19 pandemic has severely affected individuals with hematological malignancies due to their weakened immune systems, resulting in higher mortality rates and severe outcomes.
- Data from the EPICOVIDEHA registry, which compiles COVID-19 cases from these patients worldwide, was collected from 2020 to 2022, including 8,767 cases from 152 centers across 41 countries.
- Findings show a significant drop in critical infections and overall mortality rates, but hospitalization (especially in ICU) remains a serious risk factor; vaccination is linked to better survival outcomes, highlighting the need for ongoing monitoring and support for these patients.
Article Synopsis
- The study investigates the effectiveness of remdesivir on reducing mortality in COVID-19 patients, focusing on identifying specific patient groups that benefit the most from the treatment.
- Researchers analyzed data from 1160 hospitalized patients, identifying five distinct clusters based on factors like symptoms duration and lymphocyte counts, which revealed varying mortality rates among these groups.
- The findings suggest that patients with higher viral loads—characterized by lower lymphocyte counts and shorter symptom duration—showed significant mortality improvement when treated with remdesivir, validating these results in a separate patient cohort.